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Abstract The derivation of human embryonic stem cells (hESCs) brought cell therapy-based regenerative medicine
significantly closer to clinical application. However, expansion of undifferentiated cells and their directed differentiation in vitro have
proven difficult to control. This ismainly because of a lack of knowledge of the intracellular signaling events that direct these complex
processes. Additionally, extracellular factors, either secreted by feeder cells that support self-renewal and maintain pluripotency or
present in serum supplementing proprietary culture media, that influence hESC behavior are largely unknown. Xeno-free media that
effectively support long-term hESC self-renewal and differentiation to specific types of specialized cells are only slowly becoming
available. Microarray-based transcriptome analyses have produced valuable gene expression profiles of hESCs and indicated changes
in transcription that occur during differentiation.However, proteins are theactual effectors of these events and changes in their levels
do not always match changes in their corresponding mRNA. Furthermore, information on posttranslational modifications that
influence the activity of pivotal proteins is still largely missing. Over the years, mass spectrometry has experienced major
breakthroughs in high-throughput identification of proteins and posttranslational modifications in cells under different conditions.
Mass spectrometry-based proteomic techniques are being applied with increasing frequency to analyze hESCs, as well as media
conditioned by feeder cells, and have generated proteome profiles that not only support, but also complement, existing microarray
data. In this review, the various proteomic studies on hESCs and feeder cells are discussed. In ameta-analysis, comparison of published
data sets distinguished 32 intracellular proteins and 16 plasma membrane proteins that are present in multiple hESC lines but not in
differentiated cells, whichwere therefore likely to include proteins important for hESCs. In addition, 13 and 24 proteins, respectively,
were commonly found in different feeder cell lines ofmouse andhumanorigin, someofwhichmaybeextracellular signalingmolecules
that play a key role in the undifferentiated propagation of hESCs. These findings underscore the power of mass spectrometry-based
techniques to identify novel proteins associated with hESCs by studying these cells in an unbiased, discovery-oriented manner on a
proteome-wide scale.
© 2008 Elsevier B.V. All rights reserved.⁎ Corresponding author. Fax: +31 71 526 8289.
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Stem cells fascinate biologists and clinicians alike because of
their potential in the development of treatments and the
understanding of disease. This is based on their remarkable
capacity for self-renewal and ability to differentiate into a
variety of specialized cell types. Stem cells from postnatal or
adult tissues are often designated “multipotent” because
they can form various differentiated progeny, both in vivo
and in vitro, but not all cell types of the adult individual.
Some types of adult stem cells are in therapeutic use or are
undergoing clinical trials, for instance, providing a new stock
of bone marrow cells after radiation treatment for leukemia
patients or generating tissue grafts in vitro to replace
damaged skin of burn victims or bone in trauma injuries.
Embryonic stem cells (ESCs) by contrast are designated
“pluripotent” because they are able to form all of the more
than 200 cell types of the adult. They are derived from the
inner cell mass of blastocyst-stage embryos and are generally
cocultured on a monolayer of mitotically inactive mouse
embryonic fibroblast feeder cells (MEFs) or biologically
active protein matrix to promote self-renewal and prevent
differentiation. ESCs are regarded as the elite among stem
cells because of their unlimited ability to proliferate in
culture. Mouse ESCs (mESCs) are the best understood; but
over the past 10 years, since their first derivation from
human embryos (Thomson et al., 1998; Reubinoff et al.,
2000; Cowan et al., 2004), information has accumulated that
has highlighted both the differences and the similarities
between human ESCs (hESCs) and mESCs (Ginis et al., 2004).
Discussion has recently focused on the question whether
mESCs and hESCs actually represent the same developmental
stage despite common derivation from blastocysts or other(later) stages (Brons et al., 2007; Tesar et al., 2007).
Moreover, diverse derivation and culture procedures exist
in the various laboratories that have established hESC lines.
Combined with the intrinsic genetic variation between the
human samples used, this could lead to the selection of hESC
lines that exhibit substantial differences in their growth
characteristics and differentiation capabilities. To deter-
mine to what extent the hESC lines established to date differ
from each other, a large comparative study was carried out
by the International Stem Cell Initiative (2007).
Despite considerableprogress in the laboratory todirect the
in vitro differentiation of ESCs into a variety of specialized
cells, many hurdles still need to be overcome before hESC-
derived differentiated cells can be applied clinically. Identifi-
cation of self-renewal factors could be useful in controlling
rogue behavior and teratoma formation by cells after
transplantation and active signaling pathways in directing
sequential differentiation. In-depth analysis of ESCs and
extensive comparisons of the numerous mouse and human
ESC lines currently in use have in fact already provided insight
into ESC self-renewal and the pathways implicated in
differentiation, although most large-scale studies to date
have been limited to analysis at the transcriptome level.
However, in the past few years, mass spectrometry (MS)-based
proteomics has matured enough to analyze biological pro-
cesses at levels that rival those accomplished with microarray
and other high-throughput approaches (Cox and Mann, 2007).
More importantly, it is now feasible to discover and study the
estimated N200 different kinds of posttranslational modifica-
tions (PTMs) that affect protein functionandstructure (Jensen,
2006). These PTMs include, for instance, phosphorylation
(Collins et al., 2007), ubiquitination (Kirkpatrick et al., 2005),
and glycosylation (Harvey, 2005), but also methylation and
171Proteomics and human embryonic stem cellsacetylation of histones (Freitas et al., 2004; Cosgrove, 2007;
Trelle and Jensen, 2007),whichchange the epigenetic statusof
cells and thus regulate gene transcription (Azuara et al., 2006;
Meshorer and Misteli, 2006; Dai and Rasmussen, 2007).
Proteomics
Until recently, proteome analysis depended largely on the
availability of specific antibodies to visualize and quantitate
protein expression on Western blots or to study the
subcellular localization of proteins by immunofluorescence
microscopy. Fluorescently tagged proteins as well as sub-
cellular fractionation prior to Western blotting are still
frequently used to examine both the temporal and the spatial
distribution of proteins in cells. Antibody chips and peptide
arrays allow focused high-throughput analysis of the pro-
teome (Spisak et al., 2007). However, compared with
microarray-based transcriptomics, these proteomic meth-
odologies had been limited to relatively small-scale studies,
providing data only on known proteins preselected by the
investigator. MS analytical techniques used to be insensitive,
required large cellular protein inputs, and were nonquanti-
tative, but are now “coming of age.” MS has experienced
major improvements in sensitivity, accuracy, and speed of
analysis as well as dynamic range, which result not only from
continuous production of better, high-quality hardware but
also from the development of analytical software that
automates the identification of proteins deposited in curated
databases. This allows cellular processes, pathways, and
networks to be analyzed at the molecular level using a largeFigure 1 Workflow of MS-based proteome profiling. Modern-day p
protein/peptide isolation and separation, which is followed by (
identifications.variety of MS methodologies (Köcher and Superti-Furga,
2007). In contrast to antibody chips and peptide arrays, MS-
based proteomics can potentially detect any protein in a
discovery-oriented manner. Moreover, state-of-the-art MS is
not restricted to straightforward qualitative high-throughput
analysis of huge proteome samples. It extends to both relative
and absolute quantitative comparisons as well as identifica-
tion of PTMs in a time-dependent manner (Jensen, 2006).
Mass spectrometry
Workflows in present-day, large-scale proteomic experiments
generally follow the same steps: (1) sample preparation,
including protein and peptide separation; (2) MS analysis and
protein identification as well as quantitation; and (3)
functional annotation of these identifications in relation to
biological questions (Fig. 1). Optimization and technical
improvement of each step have been aimed at addressing the
major recurring bottlenecks in proteomics: the enormous
complexity of proteomes and the dynamic range of protein
concentrations, which can easily span 10 orders of magni-
tude. Fractionation strategies are very effective in reducing
the complexity of samples, and therefore separation of
proteins and peptides in one or multiple dimensions has
gained popularity. Classical separation techniques include
two-dimensional separation of proteins in gels, but these
have been complemented by liquid-based separation, such as
strong-cation exchange (SCX), strong-anion exchange, and
isoelectric focusing. When focusing on a specific subset of
proteins, targeted purification of certain classes of proteinsroteomics of cells usually involves three consecutive steps: (1)
2) mass spectrometry and concludes with (3) connotation of
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(e.g., phosphorylated proteins; Pinkse et al., 2004) is often
advantageous. Virtually all applications in proteomics include
a proteolytic treatment (e.g., with trypsin) at some point in
the fractionation process, producing peptides that can be
separated effectively by reverse-phase chromatography,
which is often coupled inline with a mass spectrometer. In a
typical experiment, as many individual peptides as possible
are isolated to determine the mass of the intact peptide and
of its fragments that are produced upon its dissociation. It is
this fragmentation pattern that is most informative for
peptide identification, which can be determined bymatching
this pattern to all possible peptides that could be expected
(e.g., the human proteome). With increased scan speeds of
modern mass spectrometers, delivering several fragmenta-
tion spectra per second, and the considerable number of
liquid chromatography (LC)-MS runs that is typically involved,
this workflow easily produces tens of thousands of spectra.
Development of software applications has greatly facilitated
both processing of these spectra and linking them to peptide
identification. This often extends to identification of protein
isoforms and the possibility of searching for PTMs.
With these workflows for qualitative analysis in place,
recent applications have extended to quantitative analyses.
This often involves the tagging of proteins in one sample with
a stable isotope, which can then be mixed with an unlabeled
sample. In such an approach, the mass spectrometer resolves
heavy (labeled) from light (unlabeled) peptides, while the
intensities of the spectral peaks they produce directly reflect
their relative abundance in the respective samples. Espe-
cially the labeling of cells in culture with isotope-labeled
amino acids (e.g., [13C]Arg) (Mann, 2006) has gained
tremendous interest in a wide variety of applications, since
it has facilitated the process of singling out proteins that are
different between two samples, thus providing clues
explaining biological differences (Ong and Mann, 2005).
Combined with statistical analyses, this will limit the subset
of proteins and their modifications that are most relevant for
follow-up experiments to investigate their biological sig-
nificance [e.g., by protein knock-down (Ivanova et al., 2006)
or site-directed mutations (Cravatt et al., 2007)].
Proteome analysis of stem cells
The advances in MS-based analytical techniques have con-
siderably enhanced the possibility of analyzing stem cells at a
proteome-wide scale. Consequently, a concomitant increase
in the number of large-scale proteomic analyses of stem cells
has been observed. In 2003, Unwin and co-workers reviewed
conventional as well as MS-based proteomic techniques
available and suggested how these could be applied to study
stemcells by giving exampleswith nonstem cells (Unwin et al.,
2003). At that time, only a few investigations of stem cells had
used proteomic techniques other than those involving anti-
bodies. Three years later, the same group emphasized the
importance of combining transcriptome and proteome ana-
lyses to provide a complete picture of stem cell behavior
(Unwin and Whetton, 2006). Klemm and Schrattenholz gave a
more pharmaceutical perspective by highlighting the potential
of proteomic technologies to screen for neurotoxic effects that
active compounds could have on human embryos by using
hESCs instead of animal cells or tissues (Klemm and Schrat-tenholz, 2004). Roche and co-workers discussed all available
proteomics studies carried out to characterize mesenchymal
stem cells (MSCs; Roche et al., 2006). In a more recent review
Park and co-workers compiled an elaborate list of MSC-
associated proteins they suggested could be used as a
reference map for their proteome (Park et al., 2007). These
adult progenitors of mesoderm cells are considered likely
candidates for tissue-engineered replacement of osteoblasts,
chondrocytes, adipocytes, and stromal cells; this is primarily
because their use may be autologous and unlikely to induce
host-versus-graft immunological responses. Recently, Bahar-
vand and co-workers published a comprehensive overview of
the different types of analytical strategies used to date to
profile the proteomes of stem cells (Baharvand et al., 2007).
Interestingly, details on the cells used, passage number,
differentiation, proteomic approach, and number of protein
identifications and a brief note summarizing the major results
were included. In an earlier review by Van Hoof and co-
workers, proteomic analyses of mouse and human ESCs were
compared (Van Hoof et al., 2006b). At that time, the
availability of MS-generated proteome data sets of hESCs was
limited to a single study (Van Hoof et al., 2006a, reviewed in
Maltman and Przyborski, 2007), restricting comparison
between different cell lines of the same species to mESCs.
Since then, several proteomics studies involving hESCs and
their differentiated derivatives have been published. Ma and
co-workers concisely combined data on advancements in high-
throughput technologies applied to investigate the genome,
transcriptome, and proteome of embryonic, neural, and
hematopoietic stem cells (Ma et al., 2007). Stanton and
Bakre discussed the characterization of ESCs at the transcrip-
tome, proteome, and epigenome levels in a succinct overview
(Stanton and Bakre, 2007). Recently, Choi and co-workers
briefly reviewed a very limited number of MS-based studies on
human stemcells (Choi et al., 2007). The reviewherewill focus
specifically on the proteomic analyses of hESCs and the results
relevant to conditions sustaining self-renewal. The various
strategies to generate proteome profiles of hESCs, in
particular those generated with MS-based techniques, are
discussed and the resulting proteome data sets are compared.
Mass spectrometry-based proteome analysis of
human embryonic stem cells
Comparison of undifferentiated and differentiated
human embryonic stem cells
The first MS-derived proteome profile of hESCs to appear
online was published in 2006 and is still the largest and most
comprehensive data set of hESCs to date (Van Hoof et al.,
2006a, reviewed in Maltman and Przyborski, 2007). The
strength of this study was that the proteome profile of hESCs
was compared directly with that of a heterogeneous pool of
differentiated derivatives. This allowed elimination of
proteins that were present in both data sets, resulting in a
list of proteins that were identified uniquely in hESCs.
Undifferentiated hESCs (line HES-2; Reubinoff et al., 2000)
were cocultured on MEFs and collected by manual excision
from these monolayers for sample preparation. Differentia-
tion was induced by growing hESCs in the absence of MEFs for
12days; the diverse types of differentiated cells thus ge-
Figure 2 Venn diagram showing the overlap between pro-
teome profiles of HES-2 hESCs, differentiated HES-2 cells, and
the three Royan hESC lines combined. Of the 1775 proteins
identified in HES-2 hESCs (Van Hoof et al., 2006a) (light yellow
circle), 32 were also found among the 434 proteins detected in
each of the three Royan hESC lines (Baharvand et al., 2006)
(orange circle), but absent from the list of 1532 proteins
identified in differentiated HES-2 cells (Van Hoof et al., 2006a)
(dark yellow circle). The 32 proteins of this subset are listed in
Table 1. The number of proteins in each subset is shown in red.
173Proteomics and human embryonic stem cellsnerated were harvested collectively. Protein extracts of both
pools were separated by 1D SDS-PAGE followed by nanoflow
liquid chromatography (nanoLC) and analyzed by Fourier
transform ion cyclotron tandem MS. This strategy resulted in
the identification of 1775 nonredundant proteins in hESCs
and 1532 in their differentiated progeny, with a false-
positive rate of b0.2%. Comparing the data sets distinguished
639 proteins that were exclusively identified in hESCs,
including established ESC protein benchmarks, such as
alkaline phosphatase and SALL4 (Zhang et al., 2006, Elling
et al., 2006, Wu et al., 2006) as well as the telomeric protein
RIF1. Among the uncharacterized proteins in this subset may
be novel ESC-specific markers or proteins involved in
processes supporting self-renewal. Notably, a similar strat-
egy was applied using mESCs (line D3; Doetschman et al.,
1985), realizing an interspecies comparison, which assigned
191 proteins to a list that is unique for both human andmouse
ESCs combined (Van Hoof et al., 2006a). In other words, this
list contains candidates for generic ESC-associated proteins
that are conserved among different species.
The large-scale MS-based analysis was validated using
conventional proteomics techniques, like Western blotting,
immunofluorescence confocal microscopy, and fluorescence-
activated cell sorting (FACS) (Van Hoof et al., 2006a).
However, the evaluation was limited to the availability of
appropriate antibodies recognizing a selection of proteins
that were representatives of the different subsets. Two other
hESC lines, HUES-1 (Cowan et al., 2004) and NL-HESC-01 (Van
de Stolpe et al., 2005), were included in the verification
study to address concomitantly the issue of whether those
proteins markedly enriched in HES-2 hESCs could be used as
universal hESC benchmarks. As expected, most were found to
be enriched in all three hESC lines to similar extents.
Moreover, topoisomerase 2A (TOP2A) proved a genuine hESC-
specific marker, having no detectable expression level in
differentiated cells under the culture conditions applied.
Comparison of various human embryonic
stem cell lines
At about the same time, Baharvand and co-workers con-
ducted an MS-based investigation involving two diploid hESC
lines (Royan H2 and Royan H5) and a 69 XXY triploid hESC line
(Royan H3), the results of which were published online
(Baharvand et al., 2006) soon after the article discussed
above (Van Hoof et al., 2006a). In contrast to the study by Van
Hoof and co-workers (2006a), the three hESCs used here were
grown in the absence of feeder cells on Matrigel in MEF-
conditioned medium supplemented with basic fibroblast
growth factor (bFGF). Triplicate samples of each cell line
were subjected to 2D SDS-PAGE; only those spots present
consistently in each replicate were selected and excised for
matrix-assisted laser desorption/ionization tandem time-of-
flight (MALDI TOF/TOF) MS/MS analysis. Of the 844 spots
analyzed, 685 could be identified, representing 434 unique
proteins and 251 isoforms or posttranslationally modified
forms. Most of the proteins identified were classified as
chaperones, heat shock proteins, components of the protea-
some and ubiquitin machinery, or oxidative stress-responsive
proteins, but also included those involved in cell proliferation
and differentiation. One of the main conclusions was thatRoyan H2 and Royan H5 are more similar to each other
(correlation coefficient 0.945) than to Royan H3 (correlation
coefficient 0.915 and 0.914, respectively) with respect to
protein expression, which could be explained by the
difference in chromosome number revealed by karyotyping.
Visualizing the proteome profiles of HES-2 hESCs and
differentiated cells (Van Hoof et al., 2006a) as well as that of
the Royan hESC lines combined (Baharvand et al., 2006) in a
Venn diagram shows the overlap between the different data
sets (Fig. 2). Of the 1775 proteins identified in HES-2 hESCs,
1136 (64.0%) were also detected in their differentiated
derivatives, suggesting that the majority of the identifications
are proteins needed for general cellular processes. A similar
overlap was seen with Royan hESCs and differentiated HES-2
cells; 281 of the 434 Royan hESC proteins (64.7%) were also
found in differentiated cells. However, the HES-2 and Royan
hESCs data sets had only 294 proteins in common, 32 of which
were identified exclusively in undifferentiated cells (Fig. 2;
Table 1). The relatively small overlap could be the result of
differences in genetic background, derivation procedures,
and culture conditions as well as different sample preparation
methodologies and analytical techniques. Nevertheless, the
32 proteins listed in Table 1 may play important roles in self-
renewal processes, as they are shared by all the hESC lines
investigated, but were not identified in differentiated cells.
Plasma membrane proteins of human
embryonic stem cells
Recently, Dormeyer and co-workers conducted an extensive
MS-based comparative analysis of the plasma membrane
proteomes of hESCs and human embryonal carcinoma cells
(hECCs) (Dormeyer et al., in press). Both the inaccessibility
of proteins embedded in the lipid bilayer and the hydro-
Table 1 Proteins identified in HES-2 hESCs (Van Hoof et al.,
2006a) as well as in each of the three Royan hESC lines
(Baharvand et al., 2006), but not in differentiated HES-2
cells (Van Hoof et al., 2006a)
Gene symbol Description
ACTL6A Actin-like 6A
ACY1 Aminoacylase 1
AHSA1 Activator of heat shock 90-kDa protein
ATPase homolog 1
ALDH1B1 Aldehyde dehydrogenase 1B1 precursor
ANXA7 Annexin VII
BCAS2 Breast carcinoma amplified sequence 2
CALU Calumenin
CASP3 Caspase 3
CIAPIN1 Cytokine-induced apoptosis inhibitor 1
DNAJC9 DnaJ homolog, subfamily C, member 9
EIF3S3 Eukaryotic translation initiation factor 3,
subunit 3
EIF3S4 Eukaryotic translation initiation factor 3,
subunit 4
EIF4A2 Eukaryotic translation initiation factor 4,
subunit 2
EXOSC4 Exosome component 4
IDH3A Isocitrate dehydrogenase 3 (NAD+) α
KIAA1576 KIAA1576 protein
MTX2 Metaxin 2
NAP1L4 Nucleosome assembly protein 1-like 4
NT5C 5′,3′-nucleotidase, cytosolic
PDHA1 Pyruvate dehydrogenase (lipoamide) α1
POLR1C Polymerase (RNA) I polypeptide C
RBBP4 Retinoblastoma-binding protein 4
RFC2 Replication factor C2 (40kDa)
RNASEH2A Ribonuclease H2, subunit A
RPA2 Replication protein A2, 32kDa
SF3A3 Splicing factor 3a, subunit 3
SMARCB1 SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily b, member 1
SMS Spermine synthase
STOML2 Stomatin (EPB72)-like 2
SUCLA2 Succinate-CoA ligase, ADP-forming,
β subunit
THOC3 THO complex 3
UBQLN1 Ubiquilin 1
Figure 3 Venn diagram showing the overlap between pro-
teome profiles of HES-2 hESCs, HUES-7 hESCs, and the three
Royan hESC lines combined. A total of 1077 proteins were
identified in HUES-7 hESCs (Dormeyer et al., in press) (purple
circle), 237 of which were annotated or predicted as plasma
membrane proteins (gray circle). Of the 639 proteins detected in
HES-2 hESCs, but absent from their differentiated derivatives
(Van Hoof et al., 2006a) (yellow circle), 75 were among those
identified in HUES-7 hESCs (Dormeyer et al., in press); 16 of the
latter subset belonged to those labeled as plasma membrane
proteins and are listed in Table 2. Only 4 of the 153 proteins found
in the three Royan hESC lines (Baharvand et al., 2006), but not in
differentiated HES-2 cells (Van Hoof et al., 2006a) (orange circle)
were also identified in HUES-7 hESCs (Dormeyer et al., in press)
(purple circle). The number of proteins in each subset is shown in
red. The plasma membrane proteins are indicated in gray.
174 D. Van Hoof et al.phobicity of their transmembrane domains make plasma
membrane proteins exceptionally hard to study. Due to the
limited amount of starting material available, the research-
ers’ first intention was to optimize a sample preparation
procedure that is compatible with MS-based analytical
methods. Using the protocol with the highest yield in terms
of absolute numbers, they were able to identify 237 and 219
plasma membrane proteins in hESCs (line HUES-7; Cowan et
al., 2004) and hECCs (line NT2/D1), respectively. This
protocol basically involved mild mechanical lysis of the
cells followed by slow centrifugation to remove intact nuclei
and endoplasmic reticulum. The remaining cellular mem-
branes were harvested by ultracentrifugation onto a sucrose
cushion, after which the membrane-associated proteinswere cleaved by three subsequent digestion steps. Although
Nunomura and co-workers identified 324 proteins in mESCs
using a biotinylation-based approach to label cell surface
proteins prior to sample preparation (Nunomura et al.,
2005), only 118 were actually classified as plasma membrane
proteins based on gene ontology (GO) annotation (Dormeyer
et al., in press), and 104 times more cells were used. Thus,
the absolute number of plasma membrane proteins identi-
fied by Dormeyer and co-workers was significantly higher.
A comparison of the 1077 proteins in total detected in
HUES-7 hESCs (Dormeyer et al., in press) with the 639 proteins
uniquely identified in HES-2 hESCs (Van Hoof et al., 2006a) and
the 153 proteins present in Royan hESCs (Baharvand et al.,
2006), but absent from differentiated HES-2 cells, distin-
guished 75 and 4 proteins, respectively (Fig. 3). The latter two
subsets had no proteins in common and the 4 proteins shared
by HUES-7 cells and the Royan hESC lines were not annotated
as plasma membrane specific. On the other hand, 16 of the 75
proteins identified in both HES-2 and HUES-7 hESCs were
either annotated or predicted plasma membrane proteins
(Fig. 3). Nevertheless, in addition to putative plasma mem-
brane proteins, this list contains proteins that are unlikely to
be associated with the cell surface (e.g., LAMP1) or probably
not specific for hESCs (e.g., HLA-C) (Table 2).
Although 778 of the 1077 proteins in total identified in
HUES-7 hESCs (Dormeyer et al., in press) were not detected
Table 2 Plasma membrane proteins detected in HES-2
hESCs (Van Hoof et al., 2006a) as well as in HUES-7 hESCs
(Dormeyer et al., in press), but not in differentiated HES-2
cells (Van Hoof et al., 2006a)
Gene symbol Description
ATP2A2 ATPase, Ca2+ transporting, cardiac muscle,
slow twitch 2
BZW2 Basic leucine zipper and W2 domains 2
ERBB2 ErbB-2
FADS2 Fatty acid desaturase 2
GNAQ Guanine nucleotide binding protein
(G protein), q polypeptide
GNB2 Guanine nucleotide-binding protein,
β2 subunit
GPC4 Glypican 4
HLA-C Human leukocyte antigen, HLA-C
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene
homolog
ITGA6 Integrin α chain, α6
LAMP1 Lysosomal-associated membrane protein 1
LRP1 Low-density lipoprotein-related protein 1
(α2-macroglobulin receptor)
PTK7 PTK7 protein tyrosine kinase 7
SLC1A5 Solute carrier family 1 (neutral amino acid
transporter), member 5
SLC25A3 Solute carrier family 25, member 3
TACSTD1 Tumor-associated calcium signal
transducer 1
175Proteomics and human embryonic stem cellsin differentiated HES-2 cells (Van Hoof et al., 2006a), this
does not mean they are likely to be specific for hESCs. At first
glance, the 27.8% of proteins (299 of 1077) that HUES-7 hESCs
have in common with differentiated HES-2 cells seems low
compared with the approximately 64% observed for both
HES-2 and Royan hESCs. However, the sample preparation
method used by Dormeyer and co-workers was intended to
enrich specifically for membrane proteins, whereas that
of Van Hoof and co-workers predominantly picked up so-
luble proteins. Therefore, proper selection of hESC-specific
plasma membrane proteins would require an identical me-
thodological approach for differentiated HUES-7 cells.
Nevertheless, 199 of the 237 plasma membrane proteins
identified in HUES-7 hESCs were not detected in differen-
tiated HES-2 cells and can be regarded as an amenable
addition to the data sets of HES-2 and Royan hESCs that,
when combined, comprise an impressive 875 nonredundant
hESC-associated proteins (Supplementary Table 1).
Large-scale western blot-based proteome
analysis of human embryonic stem cells
Recently, large-scale Western blotting (Lorenz et al., 2003),
involving N1000 antibodies, was applied to analyze the
proteome of hESCs (Schulz et al., 2007). In a general screen,
934 antibodies were used to analyze BG01 hESCs, resulting in
the identification of 529 proteins, 42 of which showed
multiple bands, suggesting isoforms and PTMs of proteins.
In a more focused screen, Kinexus analysis was conducted toprofile the expression of protein kinases, phosphatases, and
phosphorylated sites in cell signaling molecules, specifically.
This screen involved 140 antibodies and was applied to BG03
hESCs, identifying 85 bands that represented 38 protein
kinases, 16 phosphatases, and 22 phosphorylated sites. The
proteins identified were ordered into different categories,
including transcription factors (e.g., Oct4, SMADs, and
STATs), cell surface proteins (e.g., cadherins, connexin-43,
and integrin α2), kinases (e.g., PKAs, PKCs, and MAP kinases),
phosphatases, and proteins involved in the cell cycle (e.g.,
CDKs) and apoptosis (e.g., caspases). The subcellular
localization of some of these proteins was confirmed with
immunofluorescence microscopy. However, the major draw-
back of this strategy is that it relies heavily on the availability
of antibodies that have been shown to recognize their antigen
specifically on Western blot. Furthermore, no comparative
analysis with differentiated cells was conducted, which
makes this approach unsuited to the discovery of new ESC-
associated proteins. For instance, karyopherinα, which was
pointed out as showing the highest intensity on Western blot,
had previously been identified in hESCs by MS (Van Hoof et
al., 2006a). Expression in undifferentiated hESCs was con-
firmed with Western blot analysis, immunofluorescence
microscopy, and FACS, but this protein was also detected in
differentiated cells, albeit at lower levels (Van Hoof et al.,
2006a). Nevertheless, this methodology has a different
sensitivity compared to MS and can be used to confirm the
expression of proteins identified by other means. Addition-
ally, this approach provides an extensive list of antibodies
that could be used to detect proteins by Western blotting.
Proteome analysis of human embryonal
carcinoma cells
ECCs are derived from malignant teratocarcinomas, usually
of the testis. Like hESCs, they are capable of unlimited self-
renewal, generally under conditions less restrictive than
those used for hESC, but in general have a limited
differentiation potential (Andrews et al., 2005). Teratocar-
cinomas are regarded as a caricature of normal embryogen-
esis, which implies that ESCs and ECCs have many of the
biological mechanisms that regulate proliferation and
differentiation in common. hECCs, however, often have
specific chromosomal abnormalities, most particularly dupli-
cation of parts of chromosomes 12 and 17 (Samaniego et al.,
1990; Reuter, 2005). These are karyotypic changes that hESCs
have been shown to acquire in culture (Baker et al., 2007).
Because of their similarities and subtle differences, ECCs are
excellently suited to defining the desirable characteristics of
ESCs and identifying the unfavorable properties that lead to
formation of teratomas. Many markers that are currently
used to determine the undifferentiated state of hESCs were
originally defined as hECC markers. These include cell
surface antigens like stage-specific embryonic antigen
(SSEA)-3 (Shevinsky et al., 1982), SSEA-4 (Kannagi et al.,
1983), and TRA-1-60 and TRA-1-81; the latter two are cell
surface proteins against which antibodies were raised
(Andrews et al., 1984). Recently, protein, gene, and
microRNA expression patterns of the ECC lines NT2/D1 and
2102Ep and the karyotypically abnormal hESC line BG01V
were extensively compared with one another as well as with
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et al., 2007). The intensity and proportion of labeling when
immunophenotyping 2102Ep and BG01V by FACS, using
antibodies against Oct4, SSEA-4, and TRA-1-60, implied
that all of these cells are very similar. Overall, the results
indicated that differences do exist between the cell lines
analyzed, yet all share expression patterns associated with
hESCs, making it virtually impossible to denote a single ECC
line as the best reference for hESCs.
As mentioned above, Dormeyer and co-workers analyzed
not only the plasma membrane proteome of hESCs, but also
that of the hECC line NT2/D1 (Dormeyer et al., in press). The
results of this study provide comparable plasma membrane
protein signatures of HUES-7 hESCs and NT2/D1 hECCs,
revealing clues that might explain both their common and
their distinct behaviors. In total, 1261 proteins were
identified in NT2/D1 hECCs, 219 of which were annotated
or predicted plasma membrane proteins. Among the 725
identifications hESCs and hECCs had in common, 152 were
plasma membrane proteins. It may not be surprising that
hESCs and hECCs dedicate similar proportions of proteins to
activities such as signaling events, enzymatic reactions, and
metabolic processes; these proportions differ from those
observed for other cell types. However, hESCs and hECCs do
not always employ the same proteins, as illustrated by
receptors involved in signal transduction. For example, while
FGFR1 was identified in both cell types, FGFR substrate 2 was
detected in hESCs but not in hECCs, whereas FGFR3 and
FGFR4 were identified in hECCs only.
Most common testicular germ cell tumors have one or
more extra copies of the short (p) arm of chromosome 12,
which is associated with elevated levels of proteins encoded
by genes located in this region. Accordingly, 14 of 26 protein
products of these genes were identified in hECCs only, which
is in strong contrast to the single 12p-derived protein (i.e.,
tetraspanin-9) that was detected uniquely in hESCs (Dor-
meyer et al., in press). Many proteins were detected in both
cell lines, yet found to be differentially expressed, as based
on the number of different peptides identified per protein.
Some of these were verified using conventional methods like
Western blotting and immunofluorescence confocal laser
microscopy, which confirmed the possibility of detecting
dissimilar expression levels with a semiquantitative
approach. Overall, the results imply that among the proteins
expressed exclusively by hECCs, or highly upregulated
compared with hESCs, might be those responsible for the
malignant nature of hECCs. However, further analyses are
required to disclose the functions of these potentially
tumorigenic candidates.
Secretome analysis of human embryonic stem
cell-derived mesenchymal stem cells
Even though human mesenchymal stem cells (hMSCs) are not
pluripotent, like hESCs, they are considered promising
candidates for tissue engineering- and cell-based therapies
because of their relatively versatile differentiation poten-
tial, considerable in vitro expansion capacity, and possible
autologous application. The latter would prevent, and some
studies suggest even repress, graft-versus-host immune
rejection after transplantation, something that might posea serious problem when using hESC-derived cells or tissues.
Until recently, MS-based proteome analyses of hESC-derived
cells were limited to the characterization of a heterogeneous
pool of differentiated HES-2 cells (Van Hoof et al., 2006a),
whereas proteomics techniques as such had been employed
repeatedly to detail primary hMSCs and their differentiated
progeny (Roche et al., 2006; Park et al., 2007). In a
complementary study, Sze and co-workers profiled the
secretion proteome (i.e., secretome) of hESC-derived
hMSCs (Sze et al., 2007). To this end, the polyclonal line
HUES9.E1, which was derived from HUES9 hESCs (Cowan et
al., 2004), was cultured in chemically defined, serum-free
medium supplemented with FGF2 and PDGF AB to produce
fibroblast-like cells that resembled bone marrow MSCs (Lian
et al., 2007). These cells were then maintained for 3days in
fresh defined medium, which was collected, filtered,
dialyzed using a molecular weight cutoff of 3500, and
concentrated. The resulting samples were analyzed by
multidimensional protein identification technology (Wash-
burn et al., 2001) LC-LTQ-MS/MS as well as cytokine antibody
arrays. Among the 201 different proteins identified by both
methods combined were those involved in metabolism,
defense responses, and differentiation processes like vascu-
larization, hematopoiesis, and skeletal development.
Twenty-nine proteins had been reported previously to be
secreted by MSCs derived from adult tissues (Sze et al.,
2007).
Although the authors claimed they identified more than
150 proteins that were not known to be secreted by hMSCs
(Sze et al., 2007), they had no direct evidence that these
were indeed expressed by hMSCs. It should be noted that the
cells thus generated are not bona fide hMSCs, but hESC-
derived cells that share many of the characteristics of adult
human bone marrow MSCs. Furthermore, they did not report
on the purity of the in vitro population. Their list is therefore
likely to be contaminated by proteins that were produced by
other cells present among the hESC-derived hMSCs. A
comparative analysis with conditioned medium from primary
hMSCs could confirm identifications, whereas that derived
from undifferentiated HUES9 hESCs would mark proteins not
specifically secreted by hMSCs. Nevertheless, their findings
emphasize the power of an MS-based approach to analyze the
composition of medium that contains factors important in
various signaling processes.
Proteome analysis of mouse feeder cell lines
supporting human embryonic stem cell
self-renewal
hESCs are traditionally cultured on MEFs in medium
supplemented with fetal calf serum. However, this culture
environment contains xeno-components, such as the nonhu-
man acidic nine-carbon sugar N-glycolylneuraminic acid
(Neu5Gc), against which many humans have circulating
antibodies. hESCs cannot synthesize Neu5Gc, yet this
carbohydrate was reported to be incorporated by hESCs
maintained under these traditional culture conditions
(Martin et al., 2005). Even though the presence of Neu5Gc
on hESCs was considered unlikely to cause a host-versus-graft
immune response (Cerdan et al., 2006), other xeno-
components might compromise the use of their differen-
177Proteomics and human embryonic stem cellstiated derivatives for therapeutic applications. Therefore,
new hESC lines should be derived and maintained under
conditions completely devoid of xeno-components.
Secretome analysis of STO feeder cells
MS-based analysis of the secretome of MEFs was the first
discovery-oriented investigation to seek proteins that sup-
port self-renewal of hESCs (Lim and Bodnar, 2002). Serum-
free medium was conditioned by MEFs (line STO), then
concentrated, and subjected to 2D SDS-PAGE. Of the 828
protein spots that were examined with MALDI-TOF-MS and
electrospray MS/MS, 136 were identified, less than a quarter
of which were extracellular or secreted according to their GO
annotation. In addition to proteins involved in growth and
differentiation, they found (residual) bovine serum compo-
nents as well as proteins associated with intracellular
processes and structures.
Secretome analysis of primary feeder cells
Xie and co-workers looked for changes in protein expression
of MEFs derived from 12.5-days postcoitum (dpc) embryos
(Kunming White strain) before and after γ-irradiation (Xie et
al., 2004). Comparing 2D gel patterns of whole-cell extracts
made from pre- and postirradiated MEFs distinguished 10
easily detectable protein spots that were present in MEFs
only after irradiation. These spots were all identified by
MALDI-TOF-MS and appeared to include cytokines and
regulators of transcription as well as proteins involved in
signal transduction, extracellular matrix formation, differ-
entiation, and apoptosis.
Secretome analysis of CD1 feeder cells
Buhr and co-workers investigated the secretome of MEFs
(line CD1) and expanded their study by including a separate
analysis of whole CD1 cell extracts as well as the porcine
gelatin on which these cells were grown (Buhr et al., 2007).
Two-dimensional SDS-PAGE followed by MALDI-TOF-MS and
nanoLC-MS/MS distinguished 110 unique proteins in MEFs, 23
in serum-containing medium, and none in gelatin due to
technical problems. These identifications were used as a
reference map to profile the proteome of mESCs that were
also investigated. Remarkably, no significant differences
were observed between unconditioned and conditioned
medium. Moreover, both media contained 15% fetal calf
serum; as a consequence, all proteins except one (i.e.,
mouse γ-actin) were of bovine origin. The lack of proteins
exclusively present in conditioned medium makes it virtually
impossible to distinguish candidates that might play a role in
self-renewal signaling pathways.
Secretome comparison of primary and ΔE-MEF
feeder cells
Serum-free medium conditioned by primary MEFs, derived
from 13.5-dpc embryos, was also compared with that
conditioned by an immortalized MEF line (ΔE-MEF), which
did not support undifferentiated growth of hESCs (Chin et
al., 2007). Both conditioned media were passed through a0.22-μm filter to remove cellular debris, concentrated with
a molecular weight cutoff of 5000, and subjected to 2D SDS-
PAGE. Of the 12 proteins found to be differentially present
in the samples derived from primary MEFs and ΔE-MEFs, 6
growth factors (MCP-1, IL-6, PAI, PEDF, IGFBP-2, and IGFBP-
7) were added to unconditioned serum-free medium
containing S1P, PDGF, and bFGF. More than 80% of the
hESCs (line HES-2) cultured on fibronectin in that medium
maintained Oct4 and TRA-1-60 expression after four
passages (i.e., 4weeks). Even after five passages under
these culture conditions, ∼70% of the hESCs (line HES-3) still
expressed these two ESC benchmarks. In contrast, hESCs
grown without these 6 growth factors were not viable after
three passages. This indicates that, although unconditioned
medium supplemented with these factors delays loss of
“stemness,” it is not as potent as serum-containing MEF-
conditioned medium, which ensures continued expression of
Oct4 and TRA-1-60 for N90% of the hESCs. Additional
components that might be required for indefinite undiffer-
entiated growth of hESCs could be present in serum, which
was not included in the assay.
Secretome analysis of primary feeder cells derived
from 129sv mice
In an elaborate investigation, Prowse and co-workers
analyzed medium conditioned by mitotically inactive
human feeder cells, which will be discussed below, and
MEFs derived from 14.5-dpc embryos of 129sv mice (Prowse
et al., 2007). Proteins in the serum-free conditioned medium
were precipitated and analyzed by 2D LC-MS/MS and 2D SDS-
PAGE followed by MALDI-TOF/TOF. This led to the identifica-
tion of 85 different proteins, which included factors
putatively involved in growth, differentiation, and main-
tenance of hESC pluripotency, as based on current literature.
Despite extensive washing of the cells before medium
conditioning was commenced, bovine proteins were also
detected; these were removed from the initial list of
identifications.
Secretome comparison of STO and primary
129sv-derived feeder cells
The large variety of experimental approaches used, as well
as the divergent focus of each study described, above limits
direct secretome comparison of STO feeders (Lim and
Bodnar, 2002) with that of primary 129sv mouse feeders
(Prowse et al., 2007). The two data sets have 33 proteins in
common. However, only 13 of these (Table 3) are likely to be
secreted according to their GO annotation (Fig. 4). The
intracellular proteins found in the medium are probably
derived from cells that died and lysed during the 16 to 18h of
growth in medium devoid of serum. Presumably, the
secretome profile of STO feeders (Lim and Bodnar, 2002) is
less accurate than that of the primary MEFs (Prowse et al.,
2007); the latter research was conducted approximately 5
years later; hence, it had the benefits of more advanced
analytical techniques and improved experimental methodol-
ogies. This is apparent from both the almost twofold higher
percentage of secretory proteins (∼24% by Lim and co-
workers versus ∼44% by Prowse and co-workers) and the
Table 3 Secreted proteins detected in medium conditioned
by STO feeders (Lim and Bodnar, 2002) as well as in medium
conditioned by MEFs derived from 14.5-dpc embryos of 129sv
mice (Prowse et al., 2007)
Gene symbol Description
COL1A1 Collagen, type I, α1
COL1A2 Collagen, type I, α2
COL3A1 Collagen, type III, α1
COL5A2 Collagen, type V, α2
COL6A1 Collagen, type VI, α1
CST3 Cystatin C precursor
GSN Gelsolin
HSPG2 Heparan sulfate proteoglycan 2
LGALS1 Lectin, galactose binding, soluble 1
MMP2 Matrix metalloproteinase 2
PCOLCE Procollagen C-proteinase enhancer protein
SERPINF1 Serine (or cysteine) proteinase inhibitor,
clade F, member 1
SPARC Secreted acidic cysteine-rich glycoprotein
Figure 4 Venn diagram showing the overlap between secre-
tome profiles of mouse-derived feeder cells that support self-
renewal of hESCs. The secretome data set of STO feeders,
containing 136 proteins (Lim and Bodnar, 2002) (dark blue
circle), and that of mouse primary feeder cells (MEFs), contain-
ing 85 proteins (Prowse et al., 2007) (light blue circle), had 33
proteins in common, 13 of which are likely to be secreted. The
number of proteins in each subset is shown in red. The numbers of
intracellular and secreted proteins indicated in the lower circle
are shown in white; the 13 secreted proteins are listed in Table 3.
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later study.
Secretome analysis of human feeder cell lines
supporting human embryonic stem cell
self-renewal
Secretome analysis of HNF02 feeder cells
In addition to Matrigel-based culture systems that would
replace feeder cells entirely, human-derived feeder cells
supporting undifferentiated propagation of hESCs may serve
as an appropriate substitute when seeking alternatives for
MEFs (Richards et al., 2003). Prowse and co-workers initially
profiled the secretome of human neonatal foreskin fibroblast
feeder cells (line HNF02), which support hESC self-renewal
(Prowse et al., 2005). The serum-free medium was collected
and concentrated, after which the TCA precipitate was
analyzed by 2D LC-MS/MS as well as 2D SDS-PAGE preceding
MALDI-TOF/TOF. The data set that resulted from combining
the two profiles contained 102 different proteins, among
which were growth factors and proteins associated with
differentiation and extracellular matrix.
Secretome comparison of HNF02, HFF01, and
mouse feeder cells
As described above, the same group later compared serum-
free media conditioned by HNF02 cells, human fetal
fibroblasts (line HFF01), and MEFs (Prowse et al., 2007).
Using a similar analytical approach as before (Prowse et al.,
2005), they identified with high reliability 73 proteins in
HNF02-conditioned medium, which is 29 less than in their
earlier investigation. The lower number of identifications in
their later study probably resulted from more stringent
selection criteria, as it contained 116 entries when a
standard approximating the previous conditions was applied.
Of the 54 proteins present in both data sets, more than half(28 proteins) were likely to be secreted based on GO
annotation.
Comparing the HNF02 data set with that of HFF01 cells is
more informative, as it distinguishes proteins expressed by
two different human feeder lines that both support self-
renewal of hESCs. The HFF01 secretome profile had 51 of its
116 proteins in common with that of HNF02 feeder cells (Fig.
5). GO annotation labeled 24 of the 51 identifications as
secretory proteins (Table 4), including factors associated
with the insulin and transforming growth factor pathways as
well as five components of collagen, four of which were also
present in the MEF subset (Table 3). Four proteins were
secreted by both of the mouse and human feeder cell lines:
galactose-binding lectin (LGALS1), matrix metalloproteinase
2 (MMP2), procollagen C-endopeptidase enhancer (PCOLCE),
and secreted protein acidic and rich in cysteine (SPARC).
LGALS1 modulates cell-cell and cell-matrix interactions and
may act as an autocrine negative growth factor that
regulates cell proliferation (Barondes et al., 1994). MMP2
degrades type IV collagen in physiological processes like
embryonic development and tissue remodeling (Corcoran et
al., 1996). PCOLCE is a glycoprotein that binds and drives the
enzymatic cleavage of type I procollagen and heightens C-
proteinase activity (Scott et al., 1999). SPARC is a matrix-
associated protein that elicits changes in cell shape, inhibits
cell-cycle progression, and influences the synthesis of
extracellular matrix (Bornstein and Sage, 2002). Whether
these proteins, recurring in each of the four different data
Table 4 Secreted proteins detected in medium conditioned
by HFF01 feeder cells as well as in medium conditioned by
HNF02 feeder cells (Prowse et al., 2007)
Gene symbol Description
BGN Biglycan preproprotein
COL1A1 Collagen, type I, α1
COL1A2 Collagen, type I, α2
COL3A1 Collagen, type III, α1
COL6A1 Collagen, type VI, α1
COL6A2 Collagen, type VI, α2
FBLN1 Fibulin 1
FN1 Fibronectin 1
FSTL1 Follistatin-like 1
GREM1 Gremlin-1
IGFBP3 Insulin-like growth factor-binding protein 3
IGFBP7 Insulin-like growth factor-binding protein 7
LGALS1 β-Galactoside-binding lectin precursor
LUM Lumican
MMP2 Matrix metalloproteinase 2
PCOLCE Procollagen C-proteinase enhancer protein
POSTN Periostin, osteoblast-specific factor
QSCN6 Quiescin Q6 sulfhydryl oxidase 1
SERPINE1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
SPARC Secreted acidic cysteine-rich glycoprotein
TF Transferrin
TGFBI Transforming growth factor, β-induced, 68kDa
THBS1 Thrombospondin 1
TIMP1 Tissue inhibitor of metalloproteinase 1
Figure 5 Venn diagram showing the overlap between secre-
tome profiles of human-derived feeder cells that support self-
renewal of hESCs. The secretome data set of HFF01 cells,
containing 116 proteins (Prowse et al., 2005) (dark green circle),
and that of HNF02 cells, containing 72 proteins (Prowse et al.,
2007) (light green circle), had 51 proteins in common, 24 of
which are likely to be secreted. The number of proteins in each
subset is shown in red. The numbers of intracellular and secreted
proteins indicated in the lower circle are shown in white; the 24
secreted proteins are listed in Table 4.
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combination, or in collaboration with factors yet unknown
needs to be validated.
Concluding remarks
hESCs have been available for research for almost a decade
(Thomson et al., 1998), during which time the numbers of
publications have risen from just a handful to more than 700
per year. They have shown their enormous capacity for
differentiation, implying significant potential for regenera-
tive medicine and providing insight into human develop-
ment and disease, as well as drug discovery and toxicity
analyses. In parallel, MS has rapidly evolved into an
extremely powerful tool, now excellently suited to the
identification of cellular and subcellular proteins, including
those of hESCs (Baharvand et al., 2007). However, a
prerequisite for applying undirected MS-based techniques
to the discovery of new hESC benchmarks is that compara-
tive studies are conducted (Van Hoof et al., 2006b).
Proteome profiles generated with advanced MS equipment
easily contain several hundreds to thousands of proteins; it
is practically impossible to determine and validate the roles
of all these candidates in the laboratory. In this review, the
different hESC-derived proteome profiles currently avail-
able were compared, resulting in a list of 875 proteins
(Supplementary Table 1) that were identified as beingcommonly expressed in several undifferentiated hESC lines
but not in immediate differentiated derivatives. However,
their mutual expression implies but does not prove func-
tional relevance. In addition, even though this list offers a
good basis for identifying hESC-specific proteins, it is huge
and ideally should be subjected to further screens eliminat-
ing proteins known to be involved in differentiation that
normally takes place much later in development. Selecting
proteins identified in HES-2 hESCs as well as Royan hESCs or
HUES-7 hESCs, while excluding those found in differentiated
HES-2 cells, distinguished 32 intracellular proteins (Table 1)
and 16 plasma membrane proteins (Table 2). Since these
proteins were identified in undifferentiated cells only, all
are likely to play a pivotal role in hESCs, yet each requires
validation with conventional molecular and cellular biology
techniques.
Notably, some proteins, associated with undifferentiated
hESC and demonstrated as essential for their self-renewal,
such as Sox2 (Avilion et al., 2003), have also been identified
in later differentiated progeny, like neuronal cells (Zhao et
al., 2004; reviewed in Wegner and Stolt, 2005). On the other
hand, the expression level of the transcription factor Oct4 is
known to be tightly regulated; a twofold increase in
expression in mESCs results in differentiation into primitive
endoderm and mesoderm, whereas repression causes differ-
entiation to trophectoderm (Niwa et al., 2000). Apparently,
stemness depends not only on whether a certain protein is
expressed, but also on the amount and presumably the
180 D. Van Hoof et al.location of that protein in ESCs. Application of heavy stable
isotopes would allow temporal quantitation of both absolute
and relative protein levels (Ong and Mann, 2005) in ESCs
maintained or induced to differentiate under different
conditions. Improving the frequently used technique based
on stable isotope labeling with amino acids in cell culture
(Ong et al., 2002) was demonstrated to be extremely
accurate when working with small numbers of hESCs (Van
Hoof et al., 2007).
Using discovery-oriented MS-based approaches, several
promising candidates that might play a role in hESC self-
renewal have been detected in media conditioned by feeder
cells that support undifferentiated propagation of hESCs.
However, most of these were annotated as intracellular
proteins that are unlikely to be secreted. Of the rest, only
few have been tested (Chin et al., 2007), and none have
actually proven to sustain the undifferentiated state of
hESCs or inhibit differentiation sufficiently over longer
periods of culture. Nevertheless, the strategies applied do
have the potential to distinguish such key factors. This is
exemplified by the identification of 13 (Table 3) and 24
(Table 4) proteins commonly found in different feeder cell
lines of mouse and human origin, respectively; the most
promising candidates among these should be validated. Even
when all proteins supporting self-renewal that are secreted
by feeder cells have been identified and added to culture
medium, serum might still turn out to contain essential
components required for undifferentiated hESC expansion in
culture. Abundant proteins like albumin are an obstacle to
straightforward proteome analysis for identifying these
essential factors in serum. Although using human serum
eliminates the risk of xeno-contamination, its source is
limited and may not be available in the quality and quantity
necessary for clinical application.
Detailing dynamics in protein expression, degradation,
PTM, and intracellular trafficking is expected to produce a
wealth of data providing insight into signaling pathways
active in hESCs. MS-based proteome analysis excels in
quantitating absolute as well as relative protein levels (Ong
and Mann, 2005) and identifying PTMs, like phosphorylation
(Collins et al., 2007; Pinkse et al., 2008), in an unbiased and
discovery-oriented manner. Active proteins (e.g., those
phosphorylated) detected in the intracellular pool can be
monitored temporally, which allows examination of cell
behavior even beyond dynamics in protein expression. Even
though changes in gene transcription have a direct effect on
mRNA translation, the production, stability, and activity of
proteins is regulated by additional processes, such as
stability of mRNA, rate of translation and degradation,
PTMs, and subcellular localization. In this respect, mRNA can
be seen as an intermediate in the process of protein
synthesis. In other words, changes in the mRNA profile do
not reflect the true dynamics of protein activity or indicate
alterations of intracellular signaling events per se. Even
though transcriptome- and proteome-wide analyses have
many complementary features, they have generally been
regarded as two discrete disciplines, which is mainly because
of the incompatibility of the distinct data sets generated.
Cutting-edge proteomics can go hand in hand with state-of-
the-art genomics to identify signaling pathways necessary for
expansion and differentiation, not only of hESC themselves,
but also of the differentiated intermediates. These could inturn be expanded and information on cell surface proteins
used to select them nongenetically from mixed, differen-
tiated cell populations. Together, these approaches will bring
the goals of stem cell-based therapies one step closer.
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